Please assess the completion status of the following clinical trial:

Trial Title: Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese men and women aged 20 years or older~* Patients diagnosed as having NVG (neovascular glaucoma) with neovascularization in the anterior segment (both iris and anterior chamber angle)~* Patients with IOP (intraocular pressure) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization~Exclusion Criteria:~* Patients with angle-closure due to conditions other than NVG or complete angle-closure due to NVG~* Patients with a known or suspected ocular or peri-ocular infection~* Patients with severe intraocular inflammation in the study eye~* Women who are pregnant, suspected of being pregnant or lactating~* Patients with known allergy to aflibercept

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVG patients (Type: EXPERIMENTAL): Japanese patients with neovascular glaucoma

Based on this trial design, predict the completion outcome and termination type (if applicable).